These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8301879)

  • 1. Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease.
    Yamada T; Chong JK; Asahina M; Koguchi Y; Hirayama K
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):631-5. PubMed ID: 8301879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson's disease and progressive supranuclear palsy.
    Takahashi K; Iwaoka K; Takahashi K; Suzuki Y; Taguchi K; Yamahara K; Maeda T
    Neurosci Lett; 2021 Jul; 757():135975. PubMed ID: 34023404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
    Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.
    Ballard CG; Jones EL
    Neurology; 2010 Nov; 75(20):1760-1. PubMed ID: 20962288
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow.
    Fukui Y; Hishikawa N; Sato K; Yunoki T; Kono S; Matsuzono K; Nakano Y; Ohta Y; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2015 Oct; 357(1-2):178-82. PubMed ID: 26227830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Applause sign" helps to discriminate PSP from FTD and PD.
    Dubois B; Slachevsky A; Pillon B; Beato R; Villalponda JM; Litvan I
    Neurology; 2005 Jun; 64(12):2132-3. PubMed ID: 15985587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy.
    Yamada T; Moroo I; Koguchi Y; Asahina M; Hirayama K
    Acta Neurol Scand; 1994 Jan; 89(1):42-6. PubMed ID: 8178627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
    Arai H; Morikawa Y; Higuchi M; Matsui T; Clark CM; Miura M; Machida N; Lee VM; Trojanowski JQ; Sasaki H
    Biochem Biophys Res Commun; 1997 Jul; 236(2):262-4. PubMed ID: 9240421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease.
    Doty RL; Golbe LI; McKeown DA; Stern MB; Lehrach CM; Crawford D
    Neurology; 1993 May; 43(5):962-5. PubMed ID: 8492953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease.
    Aarsland D; Litvan I; Larsen JP
    J Neuropsychiatry Clin Neurosci; 2001; 13(1):42-9. PubMed ID: 11207328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
    Salvatore C; Cerasa A; Castiglioni I; Gallivanone F; Augimeri A; Lopez M; Arabia G; Morelli M; Gilardi MC; Quattrone A
    J Neurosci Methods; 2014 Jan; 222():230-7. PubMed ID: 24286700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid Abeta42 levels in multiple system atrophy.
    Verbeek MM; Abdo WF; De Jong D; Horstink MW; Kremer BP; Bloem BR
    Mov Disord; 2004 Feb; 19(2):238-40; author reply 240-1. PubMed ID: 14978688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.